Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Empepe Development AB
AB
Active
Org 5594974379
Bergakärrsgatan 30 B, 426 77
Västra Frölunda
Medical specialists activities
·
NACE 8622
Est. 2024 · 1 year old
0 employees
Monitor
Share
Sweden
/
Companies
/
Medical specialists activities
/
Empepe Development AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2024: 0M
0M
2024
2025: 0M
0M
2025
EBITDA
SEK millions
0M
0M
0M
-1M
-1M
2024: 0M
0M
2024
2025: 0M
0M
2025
Income statement
SEK thousands
Item
2025
2024
Revenue
−0
0
Staff expenses
−0
—
EBITDA
−78
26
Depreciation & amort.
−93
−12
EBIT
−171
14
Net financials
−19
—
Profit before tax
−189
14
Tax
—
−3
Net profit
−189
11
Balance sheet
SEK thousands
Item
2025
2024
Total assets
945
828
Equity
347
536
Long-term debt
555
274
Short-term debt
43
18
Total debt
598
292
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2024
2025
Equity ratio
36,7 %
This company
38,2 %
Market median
This company
Market median
4% below market
2024
2025
Return on equity
−54,6 %
This company
18,4 %
Market median
This company
Market median
397% below market
2024
2025
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2024
2025
Asset turnover
−0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2024
2025
Debt / equity
1,72×
This company
0,62×
Market median
This company
Market median
177% above market
2024
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-09-01 – 2024-12-31
View
PDF
More on Empepe Development AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
